<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02858908</url>
  </required_header>
  <id_info>
    <org_study_id>AMO-02-MD-2-001</org_study_id>
    <secondary_id>2016-000067-16</secondary_id>
    <nct_id>NCT02858908</nct_id>
  </id_info>
  <brief_title>Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy</brief_title>
  <official_title>A Single-Blind, Phase 2 Study To Evaluate The Safety And Efficacy Of Tideglusib 400mg Or 1000mg For The Treatment Of Adolescent And Adult Congenital And Juvenile-Onset Myotonic Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AMO Pharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AMO Pharma Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Tideglusib is safe and efficacious in the&#xD;
      treatment of adolescents and adults with congenital and juvenile-onset Myotonic Dystrophy.&#xD;
      The pharmacokinetics of tideglusib and its primary metabolite will also be investigated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 20, 2016</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse events (AEs), including serious adverse events (SAEs), between baseline to end of study.</measure>
    <time_frame>14 weeks (baseline through end of study)</time_frame>
    <description>Adverse events may be volunteered spontaneously by the subject, or discovered as a result of general, non-leading questioning by physician.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Myotonic Dystrophy 1</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - Tideglusib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 mg tideglusib, orally, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Tideglusib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg tideglusib, orally, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tideglusib</intervention_name>
    <description>Tideglusib for oral suspension,</description>
    <arm_group_label>Cohort 1 - Tideglusib</arm_group_label>
    <arm_group_label>Cohort 2 - Tideglusib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adolescents or adults with diagnosis of congenital or juvenile-onset type 1 myotonic&#xD;
             dystrophy (DM-1)&#xD;
&#xD;
          -  Diagnosis must be genetically confirmed&#xD;
&#xD;
          -  Subjects must be male or female aged 12 years to 45 years&#xD;
&#xD;
          -  Subjects must have a Clinical Global Impression - Severity (CGI-S) score of 4 or&#xD;
             greater at Screening and Run-in (V2)&#xD;
&#xD;
          -  Subjects must be ambulatory and able to complete the 10 metre walk/run test (splints&#xD;
             allowed)&#xD;
&#xD;
          -  Subject's legally authorized representative (LAR) must provide written informed&#xD;
             consent and there must be written consent or assent (as age applicable and&#xD;
             developmentally appropriate) by the subject before any study-related procedures are&#xD;
             conducted&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-ambulatory (full time) wheel chair user&#xD;
&#xD;
          -  Receiving stimulant medication&#xD;
&#xD;
          -  Receiving other medications/therapies not stable (changed) within 4 weeks prior to&#xD;
             Run-in (V2)&#xD;
&#xD;
          -  Medical illness or other concern which would cause investigator to conclude subjects&#xD;
             will not be able to perform the study procedures or assessments or would confound&#xD;
             interpretation of data obtained during assessment.&#xD;
&#xD;
          -  Current enrolment in a clinical trial of an investigational drug or enrolment in a&#xD;
             clinical trial of an investigational drug in the last 6 months&#xD;
&#xD;
          -  Women of child bearing potential who are pregnant, lactating or not willing to use a&#xD;
             protocol defined acceptable contraception method if sexually active and not surgically&#xD;
             sterile.&#xD;
&#xD;
          -  Gastrointestinal disease which may interfere with the absorption, distribution,&#xD;
             metabolism or excretion of the study medication and impact the interpretability of the&#xD;
             study results&#xD;
&#xD;
          -  Current clinically significant (as determined by the investigator) cardiovascular,&#xD;
             renal, hepatic, endocrine or respiratory disease&#xD;
&#xD;
          -  Clinically significant heart disease (in the opinion of the investigator) or second or&#xD;
             third degree heart block, atrial flutter, atrial fibrillation, ventricular&#xD;
             arrhythmias, or is receiving medication for treatment of a cardiac arrhythmia&#xD;
&#xD;
          -  A history of chronic liver disease with current out of range values for Alanine&#xD;
             transaminase (ALT), clinically relevant hepatic steatosis or other clinical&#xD;
             manifestations of ongoing liver disease&#xD;
&#xD;
          -  A history of significant drug allergy (such as Steven-Johnson syndrome, anaphylaxis)&#xD;
&#xD;
          -  A history of alcohol or substance use disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grainne Gorman, MB BCh BAO LRCP&amp;SI MRCP FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Neuroscience, Newcastle University.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Newcastle-upon-Tyne Hospitals NHS Trust</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Tyne And Wear</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>August 4, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2016</study_first_posted>
  <disposition_first_submitted>December 20, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>December 20, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 27, 2018</disposition_first_posted>
  <last_update_submitted>December 20, 2018</last_update_submitted>
  <last_update_submitted_qc>December 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myotonic Dystrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

